tc-2216
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00583544)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Neuronal acetylcholine receptor; alpha4/beta2 antagonist
Racemic compound.
Chemistry & pharmacology
Loading structure…
SMILES
c1cncc(N2CCC3(CCCN3)C2)c1- Mol. weight
- 203.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL504652 ↗
Also known as
- tc-2216
- tc-2216
- tc-2216
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00583544 | Phase 1 | Jan 1, 2007 | Targacept |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Targacept | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1